134 related articles for article (PubMed ID: 31568271)
1. In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma.
Lopci E; Novellis P; Testori A; Rahal D; Voulaz E; Bottoni E; Ferraroli GM; Crepaldi A; Ceresoli GL; Perrino M; Castello A; Alloisio M; Veronesi G; Zucali PA
Nucl Med Commun; 2019 Nov; 40(11):1179-1186. PubMed ID: 31568271
[TBL] [Abstract][Full Text] [Related]
2. The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma.
Ozmen O; Koyuncu A; Koksal D; Tatci E; Alagoz E; Demirag F; Gokcek A; Arslan N
Nucl Med Commun; 2016 Jan; 37(1):43-9. PubMed ID: 26440572
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of pretreatment volume-based quantitative
Kitajima K; Doi H; Kuribayashi K; Hashimoto M; Tsuchitani T; Tanooka M; Fukushima K; Nakano T; Hasegawa S; Hirota S
Eur J Radiol; 2017 Jan; 86():176-183. PubMed ID: 28027744
[TBL] [Abstract][Full Text] [Related]
4. FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.
Incerti E; Broggi S; Fodor A; Cuzzocrea M; Samanes Gajate AM; Mapelli P; Fiorino C; Dell'Oca I; Pasetti M; Cattaneo M; Calandrino R; Gianolli L; Di Muzio N; Picchio M
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2071-2078. PubMed ID: 29876617
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW
PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313
[TBL] [Abstract][Full Text] [Related]
6. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.
Kadota K; Kachala SS; Nitadori J; Suzuki K; Dunphy MP; Sima CS; Travis WD; Rusch VW; Adusumilli PS
J Thorac Oncol; 2012 Jul; 7(7):1192-7. PubMed ID: 22617244
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
8. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Kanemura S; Kuribayashi K; Funaguchi N; Shibata E; Mikami K; Doi H; Kitajima K; Hasegawa S; Nakano T
Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
[TBL] [Abstract][Full Text] [Related]
9. 18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.
Lococo F; Rena O; Torricelli F; Filice A; Rapicetta C; Boldorini R; Paci M; Versari A
Interact Cardiovasc Thorac Surg; 2020 Apr; 30(4):593-596. PubMed ID: 32003806
[TBL] [Abstract][Full Text] [Related]
10.
Niccoli Asabella A; Di Palo A; Altini C; Fanelli M; Ferrari C; Lavelli V; Ranieri G; Gadaleta CD; Rubini G
Hell J Nucl Med; 2018; 21(3):191-197. PubMed ID: 30411729
[TBL] [Abstract][Full Text] [Related]
11. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
Francis RJ; Segard T; Morandeau L; Lee YC; Millward MJ; Segal A; Nowak AK
Lung Cancer; 2015 Oct; 90(1):55-60. PubMed ID: 26259878
[TBL] [Abstract][Full Text] [Related]
12. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
Ohno Y; Yui M; Aoyagi K; Kishida Y; Seki S; Koyama H; Yoshikawa T
AJR Am J Roentgenol; 2019 Feb; 212(2):311-319. PubMed ID: 30512992
[TBL] [Abstract][Full Text] [Related]
13. Malignant pleural mesothelioma: initial experience in integrated (18)F-FDG PET/MR imaging.
Schaarschmidt BM; Sawicki LM; Gomez B; Grueneisen J; Hoiczyk M; Heusch P; Buchbender C
Clin Imaging; 2016; 40(5):956-60. PubMed ID: 27232931
[TBL] [Abstract][Full Text] [Related]
14. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
Pinelli V; Roca E; Lucchini S; Laroumagne S; Loundou A; Dutau H; Maldonado F; Astoul P
Respiration; 2015; 89(6):558-64. PubMed ID: 25966972
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
16.
Elliott HS; Metser U; de Perrot M; Cho J; Bradbury P; Veit-Haibach P; Hussey D; Noam T
Br J Radiol; 2018 Jun; 91(1086):20170814. PubMed ID: 29498536
[TBL] [Abstract][Full Text] [Related]
17. Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.
Fodor A; Broggi S; Incerti E; Dell'Oca I; Fiorino C; Samanes Gajate AM; Pasetti M; Cattaneo MG; Passoni P; Gianolli L; Calandrino R; Picchio M; Di Muzio N
Clin Lung Cancer; 2019 Jan; 20(1):e29-e38. PubMed ID: 30253920
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of 18F-FDG positron emission tomography in malignant peritoneal mesothelioma.
Domènech-Vilardell A; Rasiej MJ; Taub RN; Ichise M
Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):54-61. PubMed ID: 24727854
[TBL] [Abstract][Full Text] [Related]
19. Is FDG-PET/CT useful for managing malignant pleural mesothelioma?
Otsuka H; Terazawa K; Morita N; Otomi Y; Yamashita K; Nishitani H
J Med Invest; 2009 Feb; 56(1-2):16-20. PubMed ID: 19262009
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
Marin-Oyaga VA; Salavati A; Houshmand S; Pasha AK; Gharavi M; Saboury B; Basu S; Torigian DA; Alavi A
Hell J Nucl Med; 2015; 18(1):11-8. PubMed ID: 25679073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]